Haemonetics (NYSE:HAE) Price Target Raised to $90.00

Haemonetics (NYSE:HAE) had its price target raised by Mizuho from $85.00 to $90.00 in a research note released on Wednesday,Benzinga reports. They currently have an outperform rating on the medical instruments supplier’s stock.

A number of other equities analysts also recently weighed in on the stock. BTIG Research reaffirmed a “buy” rating and set a $84.00 price target on shares of Haemonetics in a research note on Friday, June 26th. Bank of America upgraded Haemonetics from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $72.00 to $80.00 in a report on Friday, May 22nd. Robert W. Baird set a $67.00 target price on Haemonetics in a report on Friday, May 8th. Citigroup reissued a “neutral” rating on shares of Haemonetics in a research report on Wednesday, July 8th. Finally, Weiss Ratings upgraded Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, June 25th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $78.89.

Haemonetics Price Performance

HAE stock opened at $77.97 on Wednesday. The stock has a market capitalization of $3.54 billion, a price-to-earnings ratio of 38.60, a price-to-earnings-growth ratio of 1.58 and a beta of 0.52. The company has a quick ratio of 1.87, a current ratio of 2.95 and a debt-to-equity ratio of 1.53. Haemonetics has a 52-week low of $47.31 and a 52-week high of $87.32. The stock’s fifty day simple moving average is $70.49 and its 200-day simple moving average is $66.25.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.01. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The firm had revenue of $346.35 million for the quarter, compared to the consensus estimate of $336.83 million. During the same period in the prior year, the business posted $1.24 earnings per share. The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Equities research analysts expect that Haemonetics will post 5.21 EPS for the current year.

Institutional Trading of Haemonetics

Several large investors have recently bought and sold shares of HAE. Kemnay Advisory Services Inc. purchased a new stake in shares of Haemonetics during the fourth quarter valued at approximately $26,000. True Wealth Design LLC grew its holdings in Haemonetics by 6,700.0% during the 4th quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 335 shares in the last quarter. Leonteq Securities AG acquired a new stake in Haemonetics during the 4th quarter valued at $30,000. EverSource Wealth Advisors LLC increased its stake in Haemonetics by 2,640.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after buying an additional 396 shares during the period. Finally, Kestra Advisory Services LLC purchased a new stake in Haemonetics during the 4th quarter worth $34,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.